We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Fecal Ribonucleic Acid (RNA) Test With Fecal Occult Blood Test (FOBT) for Detecting Colorectal Cancer and Adenoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00197405
Recruitment Status : Unknown
Verified August 2009 by Hamamatsu University.
Recruitment status was:  Recruiting
First Posted : September 20, 2005
Last Update Posted : August 4, 2009
Sponsor:
Information provided by:
Hamamatsu University

Brief Summary:
Colorectal cancer (CRC) is the second common cause of death in the Western world, and is very increasing in Japan. Fecal occult blood test (FOBT) is used routinely for CRC screening, which has been shown to reduce the incidence, morbidity, and mortality of CRC. However, there is a need to develop a novel method to improve sensitivity. The investigators reported that Fecal COX-2 assay, one of fecal RNA test, is potentially useful for colorectal cancer screening (Gastroenterology 127; 422-427, 2004). So the investigators planed to compare fecal RNA test with FOBT for detecting colorectal cancer and adenoma.

Condition or disease
Colorectal Cancer

Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Comparative Study of Fecal RNA Test With Immunochemical Fecal Occult Blood Test for Detecting Colorectal Cancer and Adenoma
Study Start Date : August 1999
Estimated Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Biospecimen Retention:   Samples Without DNA
freces, biopsy tissue samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
outpatients and inpatients of hospitals, subjects of parimary care clinics
Criteria

Inclusion Criteria:

  • Clinical diagnosis of colorectal cancer or adenoma
  • Subjects with no abnormal findings of colon

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00197405


Locations
Japan
Hamamatsu University School of Medicine Recruiting
Hamamatsu, Japan, 431-3192
Contact: Shigeru Kanaoka, M.D.    81-53-435-2261    kanaoka@hama-med.ac.jp   
Principal Investigator: Shigeru Kanaoka, M.D.         
Sponsors and Collaborators
Hamamatsu University
Investigators
Study Chair: Shigeru Kanaoka, M.D.

Responsible Party: Shigeru Kanaoka, Hamamatsu University School of Medicine
ClinicalTrials.gov Identifier: NCT00197405     History of Changes
Other Study ID Numbers: CRC-FRT-001
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: August 4, 2009
Last Verified: August 2009

Additional relevant MeSH terms:
Colorectal Neoplasms
Adenoma
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type